T1	p 304 349	patients with chronic immune thrombocytopenia
T2	p 452 599	adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per ?L .
T3	p 1503 1560	Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients
T4	i 6 17	Eltrombopag
T5	i 132 143	Eltrombopag
T6	i 155 178	thrombopoietin receptor
T7	i 274 300	eltrombopag versus placebo
T8	i 424 442	placebo-controlled
T9	i 673 732	standard of care plus 50 mg eltrombopag or matching placebo
T10	i 1377 1384	placebo
T11	i 1838 1845	placebo
T12	i 1954 1961	placebo
T13	i 2094 2105	eltrombopag
T14	i 2175 2182	placebo
T15	i 2309 2316	placebo
T16	i 2511 2518	placebo
T17	i 2657 2664	placebo
T18	i 2731 2738	placebo
T19	i 2818 2858	eltrombopag . INTERPRETATION Eltrombopag
T20	o 36 67	chronic immune thrombocytopenia
T21	o 333 349	thrombocytopenia
T22	o 490 506	thrombocytopenia
T23	o 557 572	platelet counts
T24	o 930 980	immune thrombocytopenia , and splenectomy status .
T25	o 1190 1204	platelet count
T26	o 2380 2401	thromboembolic events
T27	o 2547 2587	alanine aminotransferase concentration ,
T28	o 2684 2701	total bilirubin .
T29	o 2743 2766	serious bleeding events
T30	o 2890 2921	chronic immune thrombocytopenia